Tyligand Biotechnology

Tyligand Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of innovative small molecule drugs for oncology. The company utilizes a proprietary drug discovery platform to develop dual-mechanism therapeutics that target challenging biological pathways and "undruggable" proteins. Its lead program, TSN084, is a multi-kinase inhibitor targeting CDK8/19 and other kinases, currently undergoing Phase 1 clinical evaluation for advanced solid tumors. Tyligand's pipeline also includes promising preclinical candidates such as TSN1611, a KRAS G12D inhibitor, aimed at addressing high unmet needs in cancer treatment. The leadership team brings extensive experience from global pharmaceutical companies, driving a strategy focused on precision medicine and differentiated therapeutic profiles.